RNA nanomedPub Date : 2026-11-05Epub Date: 2026-09-05
Jad Zbib, Tamar Schlick
{"title":"Viral RNAs as Dual Graphs: Extending the Motif Universe of RNAs.","authors":"Jad Zbib, Tamar Schlick","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>In the evolving landscape of RNA research, the classification and analysis of RNA motifs is necessary to uncover the intricate mechanisms governing cellular and viral processes. Here we apply the coarse-grained RAG (RNA-As-Graphs) framework to advance the classification and understanding of RNA motifs, with a focus on expanding the RNA Motif Atlas through the inclusion of novel viral RNA structures. By analyzing 273 experimentally resolved viral RNA structures from the Protein Data Bank (PDB) using RAG dual-graph representations, we identify 14 previously uncatalogued viral RNA motifs. These motifs, which include tRNA-mimicking domains, exoribonuclease-resistant domains, and internal ribosome entry sites, expand the diversity of RNA to a total number of 197 dual-graph motifs. We applied k-means, PAM, and Ward clustering and observed substantial overlap between viral and general RNAs. The expanded library of RNA motifs and submotifs provides a resource for motif discovery and RNA design.</p>","PeriodicalId":520473,"journal":{"name":"RNA nanomed","volume":"3 2","pages":"1-12"},"PeriodicalIF":0.0,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13742247/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149373656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
RNA nanomedPub Date : 2025-08-01DOI: 10.59566/isrnn.2025.0201d
Daniel W Binzel, Congcong Xu, Katherine Binzel, Arijit Ghosh, Adam Pippin, Xin Li, Mario Sechi, Michael V Knopp, Krishan Kumar, Peixuan Guo
{"title":"RNA Nanoparticles Harboring Radioisotopes or Other Imaging Molecules for Spontaneous Tumor Targeting for Early Cancer Diagnosis.","authors":"Daniel W Binzel, Congcong Xu, Katherine Binzel, Arijit Ghosh, Adam Pippin, Xin Li, Mario Sechi, Michael V Knopp, Krishan Kumar, Peixuan Guo","doi":"10.59566/isrnn.2025.0201d","DOIUrl":"10.59566/isrnn.2025.0201d","url":null,"abstract":"<p><p>Cancer patients benefit from significantly higher survival rates if tumors are detected at early stages and prior to metastasis. Positron emission tomography (PET), computed tomography (CT), Single-Photon Emission Computed Tomography (SPECT), and other imaging techniques allow for noninvasive diagnosis of various tumors in relatively short periods. Targeted delivery of radiation is also an important approach in cancer therapy. Due to the dynamic nature of RNA, RNA nanoparticles demonstrate spontaneous tumor targeting, resulting in rapid accumulation in tumors without the use of targeting ligands. Incorporating tumor-targeting ligands on RNA nanoparticles generates enhanced tumor accumulation and targeting. Here a unique technology to specifically label three-way junction (3WJ) RNA nanoparticles is reported to carry radioisotopes or other imaging markers for cancer imaging. Two RNA nanoparticles were constructed to target prostate specific membrane antigen (PSMA) via a PSMA RNA aptamer or conjugated tert-Butyl-DCL (DCL). The spontaneous cancer homing of the RNA complex resulted in the detection of tumors with high sensitivity in mouse models, which can be applied to any cancer subtype at an early stage. Tumor accumulation occurred due to the motile and deformable nature of RNA nanoparticles, allowing for the high tumor accumulation of the imaging reagent via passing rapidly growing and leaky capillaries in the tumor vasculature. Furthermore, RNA nanoparticles conjugated with a NOTA radioisotope chelator were incubated with <sup>68</sup>Ga in a pH- and temperature-controlled environment to prevent <sup>68</sup>Ga non-specific interactions with the negatively charged phosphodiester backbone of RNA. The low pH during <sup>68</sup>Ga<sup>3+</sup> conjugation neutralized the negative charge of the phosphate backbone on the RNA, ensuring only specific radioisotope chelation to NOTA. To prove the concept of the proposed system, <sup>68</sup>Ga-labeled 3WJ was tested in a prostate cancer animal model by PET/CT. The <sup>68</sup>Ga-SF5 3WJ accumulated in and identified prostate cancer tumors with high sensitivity, resolution, specificity, and reliability. The proof-of-concept study reported in this paper is an important step in the direction of developing novel radiotherapeutic agents for various cancers. The radioisotope- or fluorophore-labelled nanoparticles were excreted from the body quickly due to the motile and deformable nature of the RNA complex, thus reducing the chance of toxicity and side effects. This molecular imaging platform, based on RNA nanoparticles, shows great promise in early diagnosis, staging, and precise treatment of any tumor subtype.</p>","PeriodicalId":520473,"journal":{"name":"RNA nanomed","volume":"2 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12523805/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145310647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
RNA nanomedPub Date : 2025-04-01DOI: 10.59566/isrnn.2025.0201e
Huiqin Bian, Changli Zhou, Hiroaki Koyama, Wen Gao, Sicheng Bian, Tao Cheng, Xiaonan Han, William Tse, Alexander Miron, Shujun Liu
{"title":"CD133-Guided RNA Nanoparticle Delivery of FTO siRNA Impairs Leukemia Resistance to Tyrosine Kinase Inhibitor Therapy.","authors":"Huiqin Bian, Changli Zhou, Hiroaki Koyama, Wen Gao, Sicheng Bian, Tao Cheng, Xiaonan Han, William Tse, Alexander Miron, Shujun Liu","doi":"10.59566/isrnn.2025.0201e","DOIUrl":"10.59566/isrnn.2025.0201e","url":null,"abstract":"<p><p>Despite the initial responses to the tyrosine kinase inhibitor (TKI) for cancer therapy, many patients often relapse with no curative regimens available. Further, the ability to target therapeutic agents to cancer cells with appropriate doses remains challenging in the clinic, especially for leukemia. Here, we show that naïve CML cells are dynamically heterogeneous in colony formation. Larger clones expand while smaller ones diminish and eventually disappear. Compared to resistant cells, parental populations, including CD44+ stem cells, form a greater number of larger, solid spheroids. Upregulation of fat mass and obesity associated protein (FTO), an RNA <i>N</i> <sup><i>6</i></sup> -methyladenosine demethylase, and stem cell markers (e.g., CD44, CD133, CD25) is more obvious in resistant cells compared to parental cells. FTO inhibitors (e.g., CS1, FB23-2) appreciably impair the growth of resistant cells either alone or in combination with nilotinib. FTO protein expression is unexpectedly upregulated by CS1 or FB23-2 treatment in multiple leukemia cell lines. We then constructed RNA nanoparticles encapsulating FTO siRNAs and conjugated with anti-CD133 RNA aptamers. We showed that, compared to negative control, these nanoparticles were taken up much more efficiently by resistant cells that highly express CD133. Treatment with the CD133-guided FTO siRNA nanoparticles efficiently silenced FTO expression in resistant cells, which leads to a significant reduction in their colony and spheroid formation. These findings offer new insights into cancer drug resistance and advance the application of RNA nanotechnology for treating leukemia. The research provides a foundation for developing novel, targeted therapies for resistant leukemia.</p>","PeriodicalId":520473,"journal":{"name":"RNA nanomed","volume":"2 1","pages":"70-88"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13089974/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147725452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
RNA nanomedPub Date : 2025-04-01DOI: 10.59566/isrnn.2025.0201b
Tanvi S Bolarum, Marina A Dobrovolskaia
{"title":"Leveraging Immunological Properties of Nucleic Acid Nanoparticles to Improve Cancer Therapy.","authors":"Tanvi S Bolarum, Marina A Dobrovolskaia","doi":"10.59566/isrnn.2025.0201b","DOIUrl":"10.59566/isrnn.2025.0201b","url":null,"abstract":"<p><p>Cancer is a systemic disorder resulting from altered molecular and cellular processes and dysfunctional body systems. One of the systems dysfunctional in cancer is the immune system. Tumors develop multiple mechanisms to escape immune surveillance and reprogram the immune cells to support cancer progression. The vicious circle of tumor-immune system interactions in cancer is often referred to as the cancer immunity cycle. Nucleic acid nanoparticles (NANPs) have recently emerged as a novel class of materials with a broad spectrum of therapeutic modalities and properties distinct from traditional therapeutic nucleic acids. Herein, we review the current literature regarding the recognition of NANPs by the immune system and explore how their intrinsic and controlled immunological properties can be leveraged to overcome the barriers to effective cancer immunotherapy created by the cancer immunity cycle.</p>","PeriodicalId":520473,"journal":{"name":"RNA nanomed","volume":"2 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12360449/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144885010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
RNA nanomedPub Date : 2024-12-01DOI: 10.59566/ISRNN.2024.0101044
Katelynn Pranger, Kenya Rosas, Dmitriy Khon, Emil F Khisamutdinov
{"title":"Applications of Surface Plasmon Resonance for Advanced Studies Involving Nucleic Acids.","authors":"Katelynn Pranger, Kenya Rosas, Dmitriy Khon, Emil F Khisamutdinov","doi":"10.59566/ISRNN.2024.0101044","DOIUrl":"https://doi.org/10.59566/ISRNN.2024.0101044","url":null,"abstract":"<p><p>Surface plasmon resonance (SPR) is increasingly recognized as one of the most widely used techniques for studying nucleic acid interactions. The main advantage of SPR is its ability to measure the binding affinities and association/dissociation kinetics of complexes in real-time, in a label-free environment, and using relatively small quantities of materials. The method is based on the immobilization of one of the binding partners, ligand, on a dedicated sensor surface. Immobilization is followed by the injection of the other partner, analyte, over the surface containing the ligand. The binding is monitored by subsequent changes in the refractive index of the medium close to the sensor surface upon injection of the analyte. In the field of Nucleic Acid, SPR has been intensively used in the study of various artificial and naturally occurring RNA/DNA molecules interaction with large molecular weight mass proteins and small organic molecules because of its ability to detect highly dynamic complexes that are difficult to investigate using other techniques. This mini review aims to provide a short guideline for setting up SPR experiments to identify nucleic acid complexes and assess their binding affinity or kinetics. It covers protocols for (i) nucleic acid immobilization methods, including biotin-streptavidin, metal ion-based affinity, and amine coupling, (ii) analyte-binding analysis, (iii) affinity and kinetic measurements, and (iv) data interpretation. Determining the affinity and kinetics of nucleic acid interactions through SPR is essential for gaining insights into molecular-level binding mechanisms, thus supporting advancements in nucleic acid nanotechnology. The review also highlights the various sections of SPR applications in nucleic acid research, including nucleic acid-probe immobilization, interactions with biomolecules, aptamer studies, and small molecule binding, concluding with perspectives on future developments in the field.</p>","PeriodicalId":520473,"journal":{"name":"RNA nanomed","volume":"1 1","pages":"44-60"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11981602/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144039852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
RNA nanomedPub Date : 2024-12-01DOI: 10.59566/isrnn.2024.0101061
Kshitij Gupta, Lorena Parlea, Mathias Viard, Katelyn Smith, Anu Puri, Joseph T Bergman, Taejin Kim, Bruce A Shapiro
{"title":"Co-incubation of Short Amphiphilic Peptides with Dicer Substrate RNAs Results in <i>β</i>-Sheet Fibrils for Enhanced Gene Silencing in Cancer Cells.","authors":"Kshitij Gupta, Lorena Parlea, Mathias Viard, Katelyn Smith, Anu Puri, Joseph T Bergman, Taejin Kim, Bruce A Shapiro","doi":"10.59566/isrnn.2024.0101061","DOIUrl":"10.59566/isrnn.2024.0101061","url":null,"abstract":"<p><p>RNA can interact with positively charged, amphiphilic peptides to cooperatively assemble into fibrils that enable RNA transport across cancer cellular membranes. RNA decreases the folding energy barrier imposed by the electrostatic repulsion between these charged peptides, thus partaking in RNA-peptide self-assembly along particular pathways in the energy landscape. Specific amphiphilic peptides capable of protecting and transporting RNA across a membrane have Type II' β-turn hairpin forming motifs in their structures, which aids self-assembly into β-sheet fibrils. We employed a set of such cationic, amphiphilic peptides that have random coiled structures in the absence of folding stimuli, to characterize the (peptides):(RNA) assembly. We subjected these complexes to extensive biophysical characterization <i>in vitro</i> and in cell culture. We show that short RNAs (such as Dicer substrate RNAs) can lead these peptides to self-assemble into β-sheet fibrils that have RNA transport capabilities and can act as non-viral delivery vectors for RNA. Modulation in the peptide sequence implicitly alters the way they bind RNA and influence the peptides' ability to transport nucleic acids across membranes.</p>","PeriodicalId":520473,"journal":{"name":"RNA nanomed","volume":"1 1","pages":"61-78"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12007892/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144005463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
RNA nanomedPub Date : 2024-12-01DOI: 10.59566/isrnn.2024.0101001
Yuanzhe Zhou, Shi-Jie Chen
{"title":"Harnessing Computational Approaches for RNA-Targeted Drug Discovery.","authors":"Yuanzhe Zhou, Shi-Jie Chen","doi":"10.59566/isrnn.2024.0101001","DOIUrl":"10.59566/isrnn.2024.0101001","url":null,"abstract":"<p><p>RNA molecules have emerged as promising therapeutic targets due to their diverse functional and regulatory roles within cells. Computational modeling in RNA-targeted drug discovery presents a significant opportunity to expedite the discovery of novel small molecule compounds. However, this field encounters unique challenges compared to protein-targeted drug design, primarily due to limited experimental data availability and current models' inability to adequately address RNA's conformational flexibility during ligand recognition. Despite these challenges, several studies have successfully identified active RNA-targeting compounds using structure-based approaches or quantitative structure-activity relationship (QSAR) models. This review offers an overview of recent advancements in modeling RNA-small molecule interactions, emphasizing practical applications of computational methods in RNA-targeted drug discovery. Additionally, we survey existing databases that catalog nucleic acid-small molecule interactions. As interest in RNA-small molecule interactions grows and curated databases expand, the field anticipates rapid development. Novel computational models are poised to enhance the identification of potent and selective small-molecule modulators for therapeutic needs.</p>","PeriodicalId":520473,"journal":{"name":"RNA nanomed","volume":"1 1","pages":"1-15"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11975998/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143813328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
RNA nanomedPub Date : 2024-01-01DOI: 10.59566/isrnn.2024.0101109
Congcong Xu, Hongran Yin, Tesla Yudhistira, Zhefeng Li, Daniel W Binzel, Peixuan Guo
{"title":"Conversion of Chemical Drugs into Targeting Ligands on RNA Nanoparticles and Assessing Payload Stoichiometry for Optimal Biodistribution in Cancer Treatment.","authors":"Congcong Xu, Hongran Yin, Tesla Yudhistira, Zhefeng Li, Daniel W Binzel, Peixuan Guo","doi":"10.59566/isrnn.2024.0101109","DOIUrl":"10.59566/isrnn.2024.0101109","url":null,"abstract":"<p><p>Active targeting-mediated nanodelivery takes advantages of ligand-receptor specificity to avoid non-specific distribution, holding great promise for the treatment of a spectrum of diseases. RNA nanoparticles have demonstrated rapid spontaneous tumor targeting and very little organ accumulation due to rapid renal clearance of non-tumor accumulated RNA nanoparticles. However available ligands for specific cells are limited, yet many chemical entities possess receptor targeting capability and remains unexplored. To provide specific tumor accumulation, a multivalent targeting strategy on RNA nanoparticles to control their <i>in vivo</i> fate is implemented. Methotrexate (MTX), a clinically approved chemotherapy was used as a tumor-targeting ligand through conjugation to our RNA nanoparticle with controlled conjugation of various copy numbers. As copies of conjugated MTX increased on the nanoparticle, the specific binding to overexpressed folate receptor was enhanced as demonstrated by flow cytometry analysis and confocal microscopy imaging. Increasing the amounts of conjugated MTX did not significantly change the nanoparticle size, Zeta potential, or cytokine induction. Increased amounts of conjugated MTX resulted in improved cell inhibition due to MTX release following cell internalization. However, increasing conjugated MTX to the RNA nanoparticles reduced the melting temperature of RNA nanoparticles and increased <i>in vitro</i> serum protein binding to the nanoparticles. Thus, <i>in vivo</i> biodistribution profiles of RNA nanoparticles revealed different behaviors based on MTX conjugation in cancer targeting and clearance. Increased copies of MTX changed the ability of nanoparticles to target tumors, accumulate in healthy organs, and rapidly clear through the urine. Nanoparticle design must be closely considered for optimized cancer targeting and therapy, providing the rationale for a proper design of RNA nanodelivery in cancer treatment.</p>","PeriodicalId":520473,"journal":{"name":"RNA nanomed","volume":"1 1","pages":"109-123"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11926850/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143694834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
RNA nanomedPub Date : 2024-01-01DOI: 10.59566/isrnn.2024.0101079
Damian Beasock, Morgan Chandler, Yasmine Radwan, Zhen Liao, Fuying Ma, Ken Webb, Martin Panigaj, Jeoung Soo Lee, Kirill A Afonin
{"title":"The Reduction of Traumatic Spinal Cord Secondary Injury by Anti-RhoA siRNA Functionalized Nucleic Acid Nanoparticles (NANPs).","authors":"Damian Beasock, Morgan Chandler, Yasmine Radwan, Zhen Liao, Fuying Ma, Ken Webb, Martin Panigaj, Jeoung Soo Lee, Kirill A Afonin","doi":"10.59566/isrnn.2024.0101079","DOIUrl":"10.59566/isrnn.2024.0101079","url":null,"abstract":"<p><p>Primary injury of the spinal cord is caused by a mechanical traumatic event which is rapidly followed by a secondary injury cascade that may evolve for several months leading to biological and functional changes. During the secondary injury, many pathophysiological pathways and process are activated including inflammation, oxidative stress, demyelination, excitotoxicity, axon degeneration, and cell death. The RhoA/Rho kinase pathway significantly contributes to spinal degeneration and regeneration and therefore represents a potential therapeutic target. Nucleic acid nanoparticles (NANPs) offer easy rational and programable design with the potential to carry on multiple synergistic therapeutic nucleic acid functional motifs. In this context we designed, synthesized, and assembled several representative NANPs decorated with multiple copies of siRNAs targeting RhoA. Subsequently we assessed NANPs' physicochemical properties, toxicity, and immunorecognition upon delivery with the nanocarrier PLGA-g-PEI (PgP), developed with the aim to select for the most immunoquiescent type of formulations. In addition, we observed that L1 neural cell adhesion molecule conjugated PgP (L1-PgP) efficiently delivered NANP-siRhoA in cultured neuroblastoma (B35) cells. RhoA mRNA expression was significantly reduced by all L1-PgP/ NANP-siRhoA relative to the untreated control, while no significant differences were observed between the different NANP-siRhoAs.</p>","PeriodicalId":520473,"journal":{"name":"RNA nanomed","volume":"1 1","pages":"79-90"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12043328/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144016202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
RNA nanomedPub Date : 2024-01-01DOI: 10.59566/isrnn.2024.0101091
Piotr Rychahou, Sijin Guo, Yinan Zhang, Nicole Rychagov, Yekaterina Y Zaytseva, Heidi L Weiss, B Mark Evers, Peixuan Guo
{"title":"pH-responsive bond as a linker for the release of chemical drugs from RNA-drug complexes in endosome or lysosome.","authors":"Piotr Rychahou, Sijin Guo, Yinan Zhang, Nicole Rychagov, Yekaterina Y Zaytseva, Heidi L Weiss, B Mark Evers, Peixuan Guo","doi":"10.59566/isrnn.2024.0101091","DOIUrl":"10.59566/isrnn.2024.0101091","url":null,"abstract":"<p><p>Emerging phenomena have signaled that RNA therapeutics will be the third milestone in pharmaceutical drug development. RNA nanoparticles display motile and deformable properties that lead to (1) fast and efficient tumor accumulation via both spontaneous and active targeting, and (2) fast renal excretion of non-tumor-accumulated nanoparticles due to RNA's negative charge and dynamic property; thus, undetectable toxicity. Here, we report the use of RNA nanoparticles to harbor the cancer-targeting ligand and chemical drugs and the design of the pH-responsive bond as a linker for the release of chemical drugs from RNA-drug complexes in endosomes or lysosomes. RNA nanoparticles constructed from a three-way junction (3WJ) core of bacteriophage phi29 packaging RNA (pRNA) offer an advanced strategy for receptor-selective drug delivery into cancer cells and has the potential to enhance the efficacy of anti-cancer therapies while mitigating dose-limiting toxicity in patients with colorectal cancer (CRC). We investigated conjugation of small-molecule drugs targeting the PI3K/mTOR pathway to 3WJ RNA nanoparticles and confirmed intracellular drug delivery by 3WJ RNA nanoparticles into CRC cells. 3WJ a, a single strand of 3WJ nanoparticle, was constructed with a pH-sensitive linkage conjugated to a dual PI3K/mTOR inhibitor, PI-103-azide. We demonstrated PI-103 conjugation to RNA under normal physiologic pH conditions and rapid pH-dependent drug release in an acidic environment. Next, we assembled FA-3WJ-PI103 nanoparticles from three single-stranded RNA, 3WJ a-PI-103, 3WJ b and 3WJ c-folate, to specifically target folate receptor alpha (FRα). Our tests demonstrated receptor-mediated uptake of FA-pRNA-PI-103 nanoparticles, pH-responsive PI-103 drug release from lysosomes and inhibition of the PI3K/mTOR pathway in CRC cells and tumor spheroids. These results confirm receptor-mediated cytosolic drug delivery by pH-responsive RNA nanoparticles and demonstrate potential of the 3WJ-drug complex as a novel strategy for receptor-selective drug delivery to cancer cells with high FRα expression.</p>","PeriodicalId":520473,"journal":{"name":"RNA nanomed","volume":"1 1","pages":"91-108"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11925213/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143672241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}